Jubilant Life Sciences Limited
Jubilant Life Sciences is seeking stakeholders' nod to raise up to $200 million (around 1,330 crore) to fund expansion, including acquisitions, and additional working capital needs, among others. The...28-04-2016
28-04-2016
Notice of Postal Ballot
Jubilant Life Sciences Ltd has submitted to BSE a Copy of the Notice of Postal Ballot.28-04-2016
Exercise of ESOP Options
Jubilant Life Sciences Ltd has informed BSE that 8,743 options under JLL Employees Stock Option Plan 2011 (Plan 2011) have been exercised by one option holder.Pursuant to the terms of Plan 2011, the Nomination, Remuneration and Compensation Committee of the Company has approved transfer of 8,743 equity shares of Re. 1 each of Jubilant Life Sciences Limited from Jubilant Employees Welfare Trust to the said option holder.26-04-2016
Intimation of Schedule of Investor / Analyst Meetings
Jubilant Life Sciences Ltd has informed BSE regarding Intimation of Schedule of Investor / Analyst Meetings.20-04-2016
Shareholding for the Period Ended March 31, 2016
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here18-04-2016
Jubilant Arm Recalls 90 Vials of Hyperthyroidism Capsule: US Regulator
Jubilant DraxImage Inc, part of the Jubilant Life Sciences Group, is recalling 90 vials of sodium iodide I 131 capsules used for treatment of hyperthyroidism made at its Kirkland, Canada facility due ...13-04-2016
Intimation of Schedule of the Non Deal Road Show on April 12, 13 and 14, 2016
Jubilant Life Sciences Ltd has informed BSE regarding "Intimation of Schedule of the Non Deal Road Show on April 12, 13 and 14, 2016".11-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Jubilant Life Sciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.11-04-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE05-04-2016
Jubilant Innovation receives upfront payment and potential milestones from its investments
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated March 29, 2016 titled "Jubilant Innovation receives upfront payment and potential milestones from its investments".29-03-2016